Pfizer announced study results from its Phase 3 Lyrica Study A0081107 evaluating the use of Lyrica (pregabalin capsules) in central neuropathic pain following spinal cord injury.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.